Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 23, 2024 (2 years ago)

Dexamethasone Sodium Phosphate injection USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Dexamethasone Sodium Phosphate injection USP, 120mg per 30mL (4mg/mL), 30 mL Multiple-Dose Vial, Rx only, Distributed by: AuroMedics Pharma LLC, 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520, Made in India, NDC 55150-239-30

Affected NDC 55150-0239-30

Compare with the code on your package — it is the most precise check available.

Drug: Dexamethasone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dexamethasone Sodium Phosphate
NDC 55150-0239
4 mg/mL Injection, Solution
Intra-Articular|intralesional|intramuscular|intravenous|soft Tissue
Eugia US LLC Rx
Recalling firm
Eugia US LLC
NDC code
55150-239-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0555-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Dexamethasone recalls

See all
Class II · Moderate risk

Dexamethasone Sodium Phosphate Injection

Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.

Ongoing Impurity / degradation Somerset Therapeutics LLC D-0398-2026
Class II · Moderate risk

Dexonto 0.4%

Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.

Ongoing Labeling / mix-up Nubratori, Inc NDC 71300-6564-1 D-0392-2025

Other recalls by Eugia US LLC

All 2024 recalls
Class III · Low risk

Lidocaine HCl Injection

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Eugia US LLC D-0552-2026
Class II · Moderate risk

Gentamicin Injection

Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Ongoing Stability / shelf life Eugia US LLC NDC 55150-401-01 D-0472-2025